Talk:Alexion Pharmaceuticals
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
Donating Soliris in Germany
[edit]...in a rare expression of good will, and hoping for more media attention <g> 46.138.95.18 (talk) 06:36, 6 November 2011 (UTC)
Alexion Pharmaceuticals page edits
[edit]Products: Soliris, Kanuma, Strensiq[1]
Revenue: US$ 2.604 bil (2015)[2]
Operating Income: US$ 536.671 mil (2015)[3]
Net income: US$ 144.385 mil (2015)[4]
Total assets: US$ 13.133230 bil (2015)[5]
Total equity: US$ 8.258616 bil (2015)[6]
Number of employees: 3,000 (2015)[7]
Website: www.alexion.com
It also employes about 3,000 people worldwide.[8]
Acquisitions
Synageva's main drug, Kanuma, received approval in the United Stations on December 8, 2015 and European approval on September 1, 2015.[9]
The Synageva acquisiton was completed on June 22, 2015.[10]
Kanuma Kanuma is also approved in the European Union[11] and Japan[12].
KateDietz (talk) 20:07, 3 November 2016 (UTC)
References
- ^ "Life-transforming Therapies". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016"". www.alexion.com. Retrieved 3 November 2016.
- ^ ""European Commission Grants Marketing Authorization for KanumaTM (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.businesswire.com. Retrieved 3 November 2016.
- ^ ""Alexion Completes Acquisition of Synageva"". www.alexion.com. Retrieved 3 November 2016.
- ^ "33. "European Commission Grants Marketing Authorization for KanumaTM (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.businesswire.com. Retrieved 3 November 2016.
{{cite web}}: horizontal tab character in|title=at position 4 (help) - ^ ""Kanuma® (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)"". www.alexion.com. Retrieved 3 November 2016.